Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 4
2011 1
2012 1
2014 2
2015 3
2016 1
2017 1
2019 1
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Shomali W, et al. Am J Hematol. 2022 Jan 1;97(1):129-148. doi: 10.1002/ajh.26352. Epub 2021 Oct 8. Am J Hematol. 2022. PMID: 34533850 Free article.
Lymphocyte-variant HE is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome (HES) is a diagnosis of exclusion. RISK-ADAPTED THERAPY: The goal of therapy is to mitigate eosinophil-mediated organ damage …
Lymphocyte-variant HE is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome …
World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Shomali W, et al. Am J Hematol. 2019 Oct;94(10):1149-1167. doi: 10.1002/ajh.25617. Am J Hematol. 2019. PMID: 31423623 Free article. Review.
Lymphocyte-variant hypereosinophilia is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome (HES) is a diagnosis of exclusion. RISK-ADAPTED THERAPY: The goal of therapy is to mitigate eosinophil-mediat …
Lymphocyte-variant hypereosinophilia is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic …
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Shomali W, et al. Am J Hematol. 2024 May;99(5):946-968. doi: 10.1002/ajh.27287. Epub 2024 Mar 29. Am J Hematol. 2024. PMID: 38551368
Lymphocyte-variant HE is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome (HES) is a diagnosis of exclusion. RISK-ADAPTED THERAPY: The goal of therapy is to mitigate eosinophil-mediated organ damage …
Lymphocyte-variant HE is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome …
Management of Hypereosinophilic Syndromes.
Roufosse F. Roufosse F. Immunol Allergy Clin North Am. 2015 Aug;35(3):561-75. doi: 10.1016/j.iac.2015.05.006. Immunol Allergy Clin North Am. 2015. PMID: 26209900 Review.
The symptomatic hypereosinophilic patient must be approached in a stepwise manner, with thorough assessment to determine whether the hypereosinophilia itself is contributing to damage and disease manifestations (thereby defining a hypereosinophilic syndrome), …
The symptomatic hypereosinophilic patient must be approached in a stepwise manner, with thorough assessment to determine whether the …
Advances in the diagnosis and treatment of eosinophilia.
Helbig G. Helbig G. Curr Opin Hematol. 2014 Jan;21(1):3-7. doi: 10.1097/MOH.0000000000000011. Curr Opin Hematol. 2014. PMID: 24322486 Review.
This review discusses a recent proposal for new terminology and classification of hypereosinophilia. The results of targeted therapy for hypereosinophilia-related disorders are also summarized. RECENT FINDINGS: A panel of multidisciplinary experts agreed on unifying defini …
This review discusses a recent proposal for new terminology and classification of hypereosinophilia. The results of targeted therapy …
Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management.
Rodriguez F, Carvalho M, Banov F. Rodriguez F, et al. Int J Pharm Compd. 2023 Nov-Dec;27(6):468-473. Int J Pharm Compd. 2023. PMID: 38100664
Food and Drug Administration recently granted an orphan drug designation for low-dose naltrexone for the treatment of complex regional pain syndrome. This article provides a case study of a patient who was treated with a low dose of naltrexone for pain associated with the …
Food and Drug Administration recently granted an orphan drug designation for low-dose naltrexone for the treatment of complex regional pain …
Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance.
Caminati M, Maule M, Benoni R, Micheletto C, Tecchio C, Vaia R, De Franceschi L, Guarnieri G, Vianello A, Senna G. Caminati M, et al. Orphanet J Rare Dis. 2023 Sep 26;18(1):302. doi: 10.1186/s13023-023-02918-9. Orphanet J Rare Dis. 2023. PMID: 37752586 Free PMC article.
Mepolizumab at the dose of 300 mg/4 weeks has been recently approved as an add-on therapy for patients with uncontrolled hypereosinophilic syndrome (HES) without any identifiable non-hematologic secondary cause. ...We investigated the efficacy and safety of m …
Mepolizumab at the dose of 300 mg/4 weeks has been recently approved as an add-on therapy for patients with uncontrolled hypereosi …
Eosinophilic pneumonias in children: A review of the epidemiology, diagnosis, and treatment.
Giovannini-Chami L, Blanc S, Hadchouel A, Baruchel A, Boukari R, Dubus JC, Fayon M, Le Bourgeois M, Nathan N, Albertini M, Clément A, de Blic J. Giovannini-Chami L, et al. Pediatr Pulmonol. 2016 Feb;51(2):203-16. doi: 10.1002/ppul.23368. Epub 2015 Dec 30. Pediatr Pulmonol. 2016. PMID: 26716396 Review.
In developed countries, EPs constitute exceptional entities in pediatric care. Clinical symptoms may be transient (Loffler syndrome), acute (<1 month and mostly <7 days), or chronic (>1 month). ...EPs are a heterogeneous group of disorders divided into: (i) …
In developed countries, EPs constitute exceptional entities in pediatric care. Clinical symptoms may be transient (Loffler syndrom …
World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
Gotlib J. Gotlib J. Am J Hematol. 2017 Nov;92(11):1243-1259. doi: 10.1002/ajh.24880. Am J Hematol. 2017. PMID: 29044676 Free article. Review.
Lymphocyte-variant hypereosinophilia is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome (HES) is a diagnosis of exclusion. RISK-ADAPTED THERAPY: The goal of therapy is to mitigate eosinophil-mediat …
Lymphocyte-variant hypereosinophilia is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic …
World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J. Gotlib J. Am J Hematol. 2014 Mar;89(3):325-37. doi: 10.1002/ajh.23664. Am J Hematol. 2014. PMID: 24577808 Free article. Review.
After evaluation of secondary causes of eosinophilia, the 2008 World Health Organization establishes a semimolecular classification scheme of disease subtypes including "myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1', chronic eosin …
After evaluation of secondary causes of eosinophilia, the 2008 World Health Organization establishes a semimolecular classification scheme o …
18 results